Santiago De Los Caballeros

Researchers are studying children and adolescents aged 10 to 19 with high-risk type 1 diabetes in the Dominican Republic to see if intermittent use of the Dexcom G7 continuous glucose monitor CGM, combined with pediatric endocrinology follow-up, diabetes education, and psychological support, can improve glucose control. This pilot longitudinal study involves 40 participants from two pediatric diabetes care centers. Participants will use the Dexcom G7 CGM during two short monitoring periods early in the study, using six sensors in total. Between and after these monitoring periods, they will return to their usual finger-stick glucose monitoring with a glucometer. In addition, participants and their families will attend scheduled medical visits, diabetes education sessions, and psychological support sessions throughout the study. During the study, information will be collected from medical records, lab results, Dexcom Clarity reports, participant glucose logs, study forms, and questionnaires. Researchers will assess changes in HbA1c, time spent in glucose target range, average glucose levels, glucose variability, episodes of low and high blood glucose, adverse events, diabetes-related distress, fear of hypoglycemia, and satisfaction with glucose monitoring. The study lasts for 12 months with regular follow-up and support visits.

Researchers are evaluating the safety and effectiveness of the ATC System, a medical device designed to mechanically remove clots and restore blood flow in patients with acute pulmonary embolism PE. This is a prospective, single-arm, interventional, multicenter study focusing on adults aged 18 to 90 years who show clinical signs of acute PE and meet specific medical criteria. Participants will undergo mechanical thrombectomy using the ATC System to treat their acute PE. The study involves a single treatment procedure with monitoring of outcomes shortly after the intervention. The safety and effectiveness of this device will be assessed at 48 hours post-procedure, with additional safety evaluations at 30 days. During the study, participants will be closely observed through clinical assessments and imaging to evaluate the devices performance and monitor for any major adverse events related to the procedure or device. Outcome measures focus on effectiveness at 48 hours and safety at both 48 hours and 30 days post-procedure. The total participation duration may vary based on follow-up assessments and clinical evaluations.